Pear therapeutics files for chapter 11 and will seek to sell assets through sales process

Boston--(business wire)--pear therapeutics, inc. (nasdaq: pear) (“the company”), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (pdts), today announced that the company and its wholly owned subsidiary, pear therapeutics (us), inc. (collectively, the “debtors”) each voluntarily filed for protection under chapter 11 (“chapter 11”) of the u.s. bankruptcy code (the “bankruptcy code”) in the united states bankruptcy court for the district of delaware (the “bankruptcy court”) and they intend to pursue a sale of the business or assets under section 363 of the bankruptcy code.
PEAR Ratings Summary
PEAR Quant Ranking